CK2-IN-18
CK2-IN-18 is a protein kinase CK2 inhibitor with an IC50 of > 30 μM against protein kinase CK2. CK2-IN-18 can be used in studies related to CK2-mediated signaling pathways, such as various cancers including lung cancer and breast cancer.
For research use only. We do not sell to patients.
- CAS No.: 1417638-06-2
- Formula: C14H15N3O4
- Molecular Weight:289.29
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
CK2 |
In Vitro
CK2-IN-18 (compound 19) does not potently inhibit recombinant human CK2, with an IC50 greater than 30 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 1417638-06-2
-
Molecular Weight 289.29
-
Formula C14H15N3O4
-
SMILES
O=C1N=C(NC(CCC)=C1)NC2=CC=C(C(C(O)=O)=C2)O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)